News
The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...
Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...
Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.
Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results